COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Povidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi,
and viruses. It has been previously used in both intranasal preparations against Methicillin
Resistant Staphylococcus Aureus (MRSA) as well as oral preparations in in-vitro studies of
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle Eastern Respiratory Syndrome
Coronavirus (MERS-CoV), influenza H1N1, and rotavirus with good efficacy. This study will
evaluate the efficacy of PVP-I as prophylaxis in Coronavirus Disease 2019 (COVID19)-negative
front-line health care workers, hospital patients, and community members.